Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Cavanagh Jamie, MD, Honorata Giongco Baylon, MD, Priscilla B. Caguioa, MD, Faith E. Davies, MD, Mecide Gharibo, MD, Shiro Akinaga, PhD, Michael R. Kurman, MD, Barbara A. Novak, BS, Kwee L. Yong, PhD

Blood (2013) 122 (21): 1967.

https://doi.org/10.1182/blood.V122.21.1967.1967

Published: 2013

Journal Articles

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Takashi Ishida, MD, PhD, Michinori Ogura, MD, PhD, Kiyohiko Hatake, Masafumi Taniwaki, MD, PhD, Kiyoshi Ando, MD, PhD, Kensei Tobinai, MD, PhD, Katsuya Fujimoto, MD, PhD, Kazuhito Yamamoto, M.D., Ph.D., Toshihiro Miyamoto, MD, PhD, Naokuni Uike, MD, PhD, Mitsune Tanimoto, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kenichi Ishizawa, MD, PhD, Junji Suzumiya, MD, PhD, Hiroshi Inagaki, MD, PhD, Kazuo Tamura, MD, PhD, Shiro Akinaga, PhD, Masao Tomonaga, MD, PhD, Ryuzo Ueda, MD, PhD

Blood (2012) 120 (21): 795.

https://doi.org/10.1182/blood.V120.21.795.795

Published: 2012

Journal Articles

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,

Alexander E Perl, MD, Grace R Jeschke, Takashi Sato, Shiro Akinaga, Niranjan S. Rao, PhD, Maria R. Baer, MD, Mark J. Levis, MD, PhD, Martin Carroll, MD

Blood (2011) 118 (21): 3508.

https://doi.org/10.1182/blood.V118.21.3508.3508

Published: 2011

Journal Articles

Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)

Blood (2010) 116 (21): 285.

https://doi.org/10.1182/blood.V116.21.285.285

Published: 2010

Journal Articles

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

Yukimasa Shiotsu, Hitoshi Kiyoi, Yuichi Ishikawa, Ryohei Tanizaki, Makiko Shimizu, Hiroshi Umehara, Kenichi Ishii, Yumiko Mori, Kazutaka Ozeki, Yosuke Minami, Akihiro Abe, Hiroshi Maeda, Tadakazu Akiyama, Yutaka Kanda, Yuko Sato, Shiro Akinaga, Tomoki Naoe

Blood (2009) 114 (8): 1607–1617.

https://doi.org/10.1182/blood-2009-01-199307

Published: 2009

Journal Articles

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Keith W. Pratz, Jorge Cortes, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark Levis

Blood (2009) 113 (17): 3938–3946.

https://doi.org/10.1182/blood-2008-09-177030

Published: 2009

Journal Articles

Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.

Kazuhito Yamamoto, MD, PhD, Kensei Tobinai, MD, PhD, Atae Utsunomiya, MD, Kunihiro Tsukasaki, MD, PhD, Naokuni Uike, MD, PhD, Kimiharu Uozumi, MD, Masao Tomonaga, MD, Koji Matsushima, MD, PhD, Kenya Shitara, PhD, Shiro Akinaga, PhD, Ryuzo Ueda, MD, PhD

Blood (2008) 112 (11): 1007.

https://doi.org/10.1182/blood.V112.11.1007.1007

Published: 2008

Journal Articles

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, Eric J. Feldman, MD, Judith E. Karp, MD, Keith W. Pratz, MD, Niranjan S. Rao, PhD, Shiro Akinaga, PhD, Mark J. Levis, MD, PhD

Blood (2008) 112 (11): 2967.

https://doi.org/10.1182/blood.V112.11.2967.2967

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Ryohei Tanizaki, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Yuichi Ishikawa, MD, PhD, Kenichi Ishii, Makiko Shimizu, Yutaka Kanda, PhD, Yuko Sato, MD, PhD, Shiro Akinaga, PhD, Jorge Cortes, MD, Tomoki Naoe, MD, PhD

Blood (2008) 112 (11): 1640.

https://doi.org/10.1182/blood.V112.11.1640.1640

Published: 2008

Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel

Blood (2008) 112 (11): 1625.

https://doi.org/10.1182/blood.V112.11.1625.1625

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Kazutaka Ozeki, MD, PhD, Hiroshi Umehara, Makiko Shimizu, Shiro Akinaga, PhD, Tomoki Naoe, MD, PhD

Blood (2007) 110 (11): 1832.

https://doi.org/10.1182/blood.V110.11.1832.1832

Published: 2007

Journal Articles

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop Kantarjian, MD, Eric Feldman, MD, Judy Karp, MD, Allyson Pollack, Katrina Sandy, RN, Niranjan Rao, Shiro Akinaga, Mark Levis, MD

Blood (2007) 110 (11): 909.

https://doi.org/10.1182/blood.V110.11.909.909

Published: 2007

Journal Articles

Phase I Study of KW-0761, a Humanized Anti-CCR4 Antibody, in Patients (Pts) with Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATLL) and Peripheral T-Cell Lymphoma (PTCL): Preliminary Results.

Naokuni Uike, MD, Kunihiro Tsukasaki, MD, Atae Utsunomiya, MD, Kensei Tobinai, MD, Yasuo Morishima, MD, Kimiharu Uozumi, MD, Masao Tomonaga, MD, Koji Matsushima, MD, Knya Shitara, Ph.D., Shiro Akinaga, Ph.D., Ryuzo Ueda, MD

Blood (2007) 110 (11): 4492.

https://doi.org/10.1182/blood.V110.11.4492.4492

Published: 2007

Journal Articles

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G 1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

Yukimasa Shiotsu, Leonard M. Neckers, Ivo Wortman, Won G. An, Theodor W. Schulte, Shiro Soga, Chikara Murakata, Tatsuya Tamaoki, Shiro Akinaga

Blood (2000) 96 (6): 2284–2291.

https://doi.org/10.1182/blood.V96.6.2284

Published: 2000

Journal Articles

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia

Yukimasa Shiotsu, Kinya Yamashita, Fumihiko Kanai, Yoji Ikuina, Chikara Murakata, Masanao Teramura, Hideaki Mizoguchi, Tatsuya Tamaoki, Shiro Akinaga

Blood (2000) 95 (12): 3771–3780.

https://doi.org/10.1182/blood.V95.12.3771

Published: 2000

NARROW

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,

Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL)

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.

Phase I Study of KW-0761, a Humanized Anti-CCR4 Antibody, in Patients (Pts) with Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATLL) and Peripheral T-Cell Lymphoma (PTCL): Preliminary Results.

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G 1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only